Predict your next investment

HEALTHCARE | Drug Development
immuron.com.au

See what CB Insights has to offer

Stage

IPO | IPO

Date of IPO

6/8/2017

Market Cap

0.03B

About Immuron

Immuron is a microbiome company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases. Immuron has a technology platform that enables a shorter development therapeutic cycle. The company markets and sells Travelan for the prevention of travellers' diarrhoea.

Immuron Headquarter Location

Building 10 25-37 Chapman Street

Blackburn North, Victoria, 3131,

Australia

+61 388924802

Latest Immuron News

Immuron anti-diarrhoea treatment moves to US clinical trials

Nov 15, 2021

Immuron anti-diarrhoea treatment moves to US clinical trials You are here: Immuron’s Travelan anti-diarrhoea product has moved to the human clinical trial phase in a program led by the Uniformed Services University in the United States. Travelan, which is made in Melbourne and on sale through Chemist Warehouse, is a non-absorbable, safe product which is composed of anti-bacterial antibodies that work on the gut immune system. The USU, which envisages Travalen as a treatment for deployed US military personnel as well as overseas travellers, has begun manufacturing of the product which will be tested against two other non-antibiotic OTC treatment products. Travelan has already undergone extensive testing by the US Naval Research Centre (NMRC) which reported a ‘robust immune response’ from cows vaccinated with Travelan against Campylobacter and Entereotoxigenic Escherichia coli, the main bacteria causing diarrhoea. The cows’ colostrum or milk contained high levels of specific immunoglobulins against the target antigens, and antibodies capable of inhibiting the two bacteria strains. Now USU will trial the treatments and a placebo over 18 months, enrolling 1,336 patients in a randomised, double-blind multi-centre clinical trial beginning in April. Media: Immuron/Travelan

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Immuron

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Immuron is included in 1 Expert Collection, including Omics.

O

Omics

274 items

Immuron Patents

Immuron has filed 4 patents.

The 3 most popular patent topics include:

  • Diseases of liver
  • Hepatology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/17/2014

12/4/2018

Clostridiaceae, Acetylcholinesterase inhibitors, Inflammations, Fluoroquinolone antibiotics, Bacterial diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/17/2014

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/4/2018

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clostridiaceae, Acetylcholinesterase inhibitors, Inflammations, Fluoroquinolone antibiotics, Bacterial diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Immuron Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Immuron Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.